<?xml version="1.0" encoding="UTF-8"?>
<ref id="B62-vaccines-07-00074">
 <label>62.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Bouvin-Pley</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Morgand</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Meyer</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Goujard</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Moreau</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Mouquet</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Nussenzweig</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Pace</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Ho</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Bjorkman</surname>
    <given-names>P.J.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Drift of the HIV-1 Envelope Glycoprotein gp120 toward Increased Neutralization Resistance over the Course of the Epidemic: a Comprehensive Study Using the Most Potent and Broadly Neutralizing Monoclonal Antibodies</article-title>
  <source>J. Virol.</source>
  <year>2014</year>
  <volume>88</volume>
  <fpage>13910</fpage>
  <lpage>13917</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.02083-14</pub-id>
  <pub-id pub-id-type="pmid">25231299</pub-id>
 </element-citation>
</ref>
